Bullish & Foolish
Full INM fundamentals All 466 on the Survival Watch

INMINMED PHARMACEUTICALS INC.

Is Inmed Pharmaceuticals struggling financially?

Yes, by its own account. Inmed Pharmaceuticals told the SEC on 6 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$4.8M
Source filing
10-Q 6 May 2026
Balance sheet
31 Mar 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Jul 2026

  • 6months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$5.2M

÷

Cash burned over the last 12 months

$13.0M

What Inmed Pharmaceuticals told the SEC

The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. The Company expects to continue to seek additional funding through potential strategic…

INMED PHARMACEUTICALS INC., Form 10-Q, filed 6 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 395.7% share-count increase The company issued stock. Each share now owns 79.8% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt